ArticleFrontiers in medicine2026
Depression and medication adherence among chronic hepatitis B patients receiving resilience-based care versus standard care during antiviral therapy: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association between receiving a resilience-focused program in addition to standard care and depressive symptoms and medication adherence among patients with CHB receiving antiviral therapy. Methods: In this retrospective cohort study, 200 patients diagnosed with CHB and treated at our hospital's hepatology clinic between July 2022 and June 2025 were included. Based on historical records, 100 patients who voluntarily completed a structured 12-week resilience promotion program in addition to standard care formed the observation group, and 100 patients who received standard care only formed the control group. Primary outcomes at the 6-month follow-up were depressive symptom severity measured by the Patient Health Questionnaire-9 (PHQ-9) and medication adherence measured by the Medication Possession Ratio (MPR). Secondary outcomes included resilience (Connor-Davidson Resilience Scale-10, CD-RISC-10), virological response, alanine aminotransferase (ALT) normalization, quality of life (SF-36), adverse events, and healthcare utilization. To account for potential confounding by indication and baseline imbalances, multivariable linear, logistic, and Poisson regression models were used, with adjusted effect estimates and 95% confidence intervals reported. Results: At the 6-month follow-up, the observation group had lower depression scores (6.78 ± 3.45 vs. 10.23 ± 4.12), higher MPR (0.92 ± 0.08 vs. 0.78 ± 0.15), and higher resilience scores (32.45 ± 5.67 vs. 26.78 ± 6.34). Virological response (85.0% vs. 70.0%; adjusted OR 2.46, 95% CI 1.35 to 4.48) and ALT normalization (80.0% vs. 65.0%; adjusted OR 2.01, 95% CI 1.10 to 3.67) were more frequent in the observation group. SF-36 physical and mental component scores were also higher in the observation group. Adverse event incidence was similar between groups. The observation group had fewer unplanned outpatient visits ( Conclusion: In this retrospective cohort study, receiving a resilience-focused program in addition to standard care was associated with lower depressive symptoms, better medication adherence, and more favorable virological and biochemical outcomes in patients with CHB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.